The nice people at the Stem Cell Evidence Alert sent their update today. I won’t lie – most of it went right over my head. But one or two snippets have permeated in. And that is what CPD is (for me at least) – low level constantly updating on the hope that I learn something. After all a day when you learn nothing is a day wasted…
ARTICLE OF THE MONTH The
Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell
Transplant Outcomes: A CIBMTR Analysis. Implications During The
COVID-19 Pandemic. +++++ |
SELECTED ARTICLES
Allogeneic
stem cell transplantation as a curative option in relapse/refractory
diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
Bento, L., et al. (2021) Bone Marrow Transplantation
Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide.
DeZern A. E., et al (2021) Blood Advances [record in progress]
A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.
Gagelmann, N., et al. (2021) Blood Advances [record in progress]
Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis.
Goldsmith, S. R., et al. (2021) Blood [record in progress]
Defibrotide
In Hematopoietic Stem Cell Transplantation: A Multicenter Survey Study
Of The Spanish Hematopoietic Stem Cell Transplantation Group (GETH)
González Vicent, M., et al. (2021) European Journal of Haematology [record in progress]
Outcome
of T-cell-replete haploidentical stem cell transplantation improves
with time in adults with acute lymphoblastic leukemia: A study from the
Acute Leukemia Working Party of the European Society for Blood and
Marrow Transplantation.
Nagler, A., et al. (2021) Cancer [record in progress]
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia.
Pierini, A., et al. (2021) Blood Advances [record in progress]
Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups.
Robin, M., et al. (2021) Bone Marrow Transplantation [record in progress]
Adding
melphalan to fludarabine and a myeloablative dose of busulfan improved
survival after allogeneic hematopoietic stem cell transplantation in a
propensity score-matched cohort of hematological malignancies.
Shimomura, Y., et al. (2021) Bone Marrow Transplantation [record in progress]
No comments:
Post a Comment